Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy
Shuai Xu,1– 5,* Yiyao Zeng,1,2,* Xin Tan,1,2 Ge Zhang,3– 5 Anchen Xu,1,2 Huimin Fan,6 Fengyi Yu,7 Zhen Qin,3– 5 Yahui Song,6 Yufeng Jiang,1,2 Xiangyu Wang,1,2 Duoduo Zhang,8 Yuxin Nong,1,2 Dede Lian,9 Junnan Tang,3– 5 Yafeng Zhou1,2 1Department of Cardiology, The Fourth Affil...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/targeted-delivery-of-exosome-derived-mirna-185-5p-inhibitor-via-liposo-peer-reviewed-fulltext-article-IJN |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076112455991296 |
|---|---|
| author | Xu S Zeng Y Tan X Zhang G Xu A Fan H Yu F Qin Z Song Y Jiang Y Wang X Zhang D Nong Y Lian D Tang J Zhou Y |
| author_facet | Xu S Zeng Y Tan X Zhang G Xu A Fan H Yu F Qin Z Song Y Jiang Y Wang X Zhang D Nong Y Lian D Tang J Zhou Y |
| author_sort | Xu S |
| collection | DOAJ |
| description | Shuai Xu,1– 5,&ast; Yiyao Zeng,1,2,&ast; Xin Tan,1,2 Ge Zhang,3– 5 Anchen Xu,1,2 Huimin Fan,6 Fengyi Yu,7 Zhen Qin,3– 5 Yahui Song,6 Yufeng Jiang,1,2 Xiangyu Wang,1,2 Duoduo Zhang,8 Yuxin Nong,1,2 Dede Lian,9 Junnan Tang,3– 5 Yafeng Zhou1,2 1Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215000, People’s Republic of China; 2Institute for Hypertension, Soochow University, Suzhou, 215000, People’s Republic of China; 3Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China; 4Department of Cardiology, Henan Province Key Laboratory of Cardiac Injury and Repair, Zhengzhou, 450052, People’s Republic of China; 5Department of Cardiology, Henan Province Clinical Research Center for Cardiovascular Diseases, Zhengzhou, 450052, People’s Republic of China; 6Center of Translational Medicine and Clinical Laboratory, The Fourth Affiliated Hospital to Soochow University, Suzhou, 215028, People’s Republic of China; 7College of Veterinary Medicine, NC State University, Raleigh, NC, USA; 8Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China; 9Department of Intensive Care Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yafeng Zhou, Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215000, People’s Republic of China, Email Dryafengzhou@163.com Junnan Tang, Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email fcctangjn@zzu.edu.cnPurpose: Dilated cardiomyopathy (DCM) is a prevalent form of heart failure with limited therapeutic options. This study explores a novel treatment strategy involving the delivery of exosome-derived miRNA-185-5p inhibitors encapsulated in liposomes, aiming to target cardiac tissue and alleviate myocardial apoptosis and cuproptosis in DCM.Methods: The miRNA-185-5p inhibitor, identified in our previous study and extracted from exosomes, was encapsulated in liposomes functionalized with a cardiac-targeting peptide. This system was used in both in vitro and in vivo models of DCM induced by doxorubicin (DOX). We evaluated the effects of this treatment on cardiac function, apoptosis, cuproptosis, oxidative stress, and fibrosis using echocardiography, histological analysis, Western blotting, and biochemical assays.Results: In vitro experiments demonstrated that the Lipo@miR-185-5p inhibitor markedly attenuated apoptosis and cuproptosis in H9C2 cells and iPSC-derived cardiomyocytes, with a 42.6% reduction in apoptotic cell rates and over 50% downregulation of cuproptosis-related markers (both P < 0.01). In vivo, the targeted liposomal formulation significantly improved cardiac function in DOX-induced DCM mice, as evidenced by a 27.3% increase in left ventricular ejection fraction (LVEF) and a 36.5% reduction in myocardial fibrosis area (P < 0.01), along with enhanced survival. These findings underscore the therapeutic potential of this targeted delivery strategy for the treatment of dilated cardiomyopathy.Conclusion: Lipo@miR-185-5p inhibitor, utilizing exosome-derived miRNA and targeted liposomal delivery, effectively alleviates DCM-induced myocardial dysfunction. This approach represents a promising therapeutic strategy for cardiovascular diseases by targeting specific molecular mechanisms involved in heart failure.Keywords: liposome, exosome-miR-185-5p inhibitor, dilated cardiomyopathy, apoptosis, cuproptosis |
| format | Article |
| id | doaj-art-7ca1fb49a057432a95113e1f6769de59 |
| institution | DOAJ |
| issn | 1178-2013 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj-art-7ca1fb49a057432a95113e1f6769de592025-08-20T02:46:06ZengDove Medical PressInternational Journal of Nanomedicine1178-20132025-07-01Volume 20Issue 194079425105208Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated CardiomyopathyXu S0Zeng Y1Tan X2Zhang G3Xu A4Fan H5Yu F6Qin Z7Song Y8Jiang Y9Wang X10Zhang DNong Y11Lian DTang J12Zhou Y13Cardiovascular DepartmentCardiovascular DepartmentCardiovascular DepartmentDepartment of CardiologyCardiovascular DepartmentCenter of Translational Medicine and Clinical LaboratoryCollege of Veterinary MedicineDepartment of CardiologyCenter of Translational Medicine and Clinical LaboratoryCardiovascular DepartmentCardiovascular DepartmentDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyShuai Xu,1– 5,&ast; Yiyao Zeng,1,2,&ast; Xin Tan,1,2 Ge Zhang,3– 5 Anchen Xu,1,2 Huimin Fan,6 Fengyi Yu,7 Zhen Qin,3– 5 Yahui Song,6 Yufeng Jiang,1,2 Xiangyu Wang,1,2 Duoduo Zhang,8 Yuxin Nong,1,2 Dede Lian,9 Junnan Tang,3– 5 Yafeng Zhou1,2 1Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215000, People’s Republic of China; 2Institute for Hypertension, Soochow University, Suzhou, 215000, People’s Republic of China; 3Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China; 4Department of Cardiology, Henan Province Key Laboratory of Cardiac Injury and Repair, Zhengzhou, 450052, People’s Republic of China; 5Department of Cardiology, Henan Province Clinical Research Center for Cardiovascular Diseases, Zhengzhou, 450052, People’s Republic of China; 6Center of Translational Medicine and Clinical Laboratory, The Fourth Affiliated Hospital to Soochow University, Suzhou, 215028, People’s Republic of China; 7College of Veterinary Medicine, NC State University, Raleigh, NC, USA; 8Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China; 9Department of Intensive Care Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yafeng Zhou, Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215000, People’s Republic of China, Email Dryafengzhou@163.com Junnan Tang, Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email fcctangjn@zzu.edu.cnPurpose: Dilated cardiomyopathy (DCM) is a prevalent form of heart failure with limited therapeutic options. This study explores a novel treatment strategy involving the delivery of exosome-derived miRNA-185-5p inhibitors encapsulated in liposomes, aiming to target cardiac tissue and alleviate myocardial apoptosis and cuproptosis in DCM.Methods: The miRNA-185-5p inhibitor, identified in our previous study and extracted from exosomes, was encapsulated in liposomes functionalized with a cardiac-targeting peptide. This system was used in both in vitro and in vivo models of DCM induced by doxorubicin (DOX). We evaluated the effects of this treatment on cardiac function, apoptosis, cuproptosis, oxidative stress, and fibrosis using echocardiography, histological analysis, Western blotting, and biochemical assays.Results: In vitro experiments demonstrated that the Lipo@miR-185-5p inhibitor markedly attenuated apoptosis and cuproptosis in H9C2 cells and iPSC-derived cardiomyocytes, with a 42.6% reduction in apoptotic cell rates and over 50% downregulation of cuproptosis-related markers (both P < 0.01). In vivo, the targeted liposomal formulation significantly improved cardiac function in DOX-induced DCM mice, as evidenced by a 27.3% increase in left ventricular ejection fraction (LVEF) and a 36.5% reduction in myocardial fibrosis area (P < 0.01), along with enhanced survival. These findings underscore the therapeutic potential of this targeted delivery strategy for the treatment of dilated cardiomyopathy.Conclusion: Lipo@miR-185-5p inhibitor, utilizing exosome-derived miRNA and targeted liposomal delivery, effectively alleviates DCM-induced myocardial dysfunction. This approach represents a promising therapeutic strategy for cardiovascular diseases by targeting specific molecular mechanisms involved in heart failure.Keywords: liposome, exosome-miR-185-5p inhibitor, dilated cardiomyopathy, apoptosis, cuproptosishttps://www.dovepress.com/targeted-delivery-of-exosome-derived-mirna-185-5p-inhibitor-via-liposo-peer-reviewed-fulltext-article-IJNliposomeexosome-miR-185-5p inhibitordilated cardiomyopathyapoptosiscuproptosis. |
| spellingShingle | Xu S Zeng Y Tan X Zhang G Xu A Fan H Yu F Qin Z Song Y Jiang Y Wang X Zhang D Nong Y Lian D Tang J Zhou Y Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy International Journal of Nanomedicine liposome exosome-miR-185-5p inhibitor dilated cardiomyopathy apoptosis cuproptosis. |
| title | Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy |
| title_full | Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy |
| title_fullStr | Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy |
| title_full_unstemmed | Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy |
| title_short | Targeted Delivery of Exosome-Derived miRNA-185-5p Inhibitor via Liposomes Alleviates Apoptosis and Cuproptosis in Dilated Cardiomyopathy |
| title_sort | targeted delivery of exosome derived mirna 185 5p inhibitor via liposomes alleviates apoptosis and cuproptosis in dilated cardiomyopathy |
| topic | liposome exosome-miR-185-5p inhibitor dilated cardiomyopathy apoptosis cuproptosis. |
| url | https://www.dovepress.com/targeted-delivery-of-exosome-derived-mirna-185-5p-inhibitor-via-liposo-peer-reviewed-fulltext-article-IJN |
| work_keys_str_mv | AT xus targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT zengy targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT tanx targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT zhangg targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT xua targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT fanh targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT yuf targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT qinz targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT songy targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT jiangy targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT wangx targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT zhangd targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT nongy targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT liand targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT tangj targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy AT zhouy targeteddeliveryofexosomederivedmirna1855pinhibitorvialiposomesalleviatesapoptosisandcuproptosisindilatedcardiomyopathy |